[Thoracoscopic diaphragmatic plication technique in a patient with refractory hepatic hydrothorax].

Authors

Emmanuel Peña Gomez-Portugal, Cristian De Jesús García-Aguilar, Andrea Alondra Hernández-Gurrola

Published in

Revista medica del Instituto Mexicano del Seguro Social. Volume 64. Issue 5. Pages e7011. Sep 02, 2026. Epub Sep 02, 2026.

Abstract

Refractory hepatic hydrothorax (HH) is the persistent accumulation of pleural effusion secondary to portal hypertension, in the absence of cardiopulmonary or pleural etiology. It is diagnosed in patients with cirrhosis and it is a diagnosis of exclusion. Initial management consists of diuretics and sodium restriction, with a success rate of 75-80%; the remainder progress to refractory HH. Diaphragmatic plication via thoracoscopy combined with chemical pleurodesis has emerged as a therapeutic alternative to improve quality of life and reduce hospitalizations.
A 64-year-old woman with cirrhosis due to primary biliary cholangitis, Child-Pugh B (9 points), MELD 3.0: 15 points (bilirubin 1.7 mg/dL, INR 1.0, creatinine 1.3 mg/dL, sodium 140 mEq/L, albumin 2.0 g/dL). The patient presented with pleuritic pain, dyspnea mMRC IV, and transudative pleural effusion. Diuretic therapy with propranolol, furosemide, and spironolactone was administered, along with sodium restriction (80-90 mEq/day) and fluid restriction (< 2 L/day), without improvement and with symptom progression. A diagnosis of refractory HH was made, and thoracoscopic diaphragmatic plication with chemical pleurodesis was performed, resulting in a reduction of the effusion and clinical improvement. 6 months later, there was no clinical or radiological recurrence.
Diaphragmatic plication closes defects that communicate between the abdominal and pleural cavities, reducing the pleuroperitoneal gradient. Chemical pleurodesis induces pleural adhesion and obliteration of the space. The combination of both techniques increases therapeutic effectiveness.

PMID:
42771830
Bibliographic data and abstract were imported from PubMed on 23 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.